New insider activity at Bio Green Med Solution ( (BGMS) ) has taken place on November 5, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Significant shareholder Kim Choy Yap has recently sold 28,540 shares of Bio Green Med Solution stock, amounting to a total value of $48,518.
Recent Updates on BGMS stock
In recent developments, Bio Green Med Solution (BGMS) finalized an Asset Purchase Agreement with Tethra Biosciences Inc. on October 6, 2025, selling assets including patent rights related to Plogosertib for $300,000, with a potential milestone payment of $170,000. This strategic move may significantly impact the company’s market positioning by transferring key intellectual property. Additionally, BGMS announced a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock, payable on November 1, 2025. Despite these announcements, Spark, TipRanks’ AI Analyst, maintains a ‘Underperform’ rating for BGMS due to operational inefficiencies, a weak financial position, and unattractive valuation metrics, including a negative P/E ratio and lack of dividend yield, resulting in a low overall stock score.
Spark’s Take on BGMS Stock
According to Spark, TipRanks’ AI Analyst, BGMS is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on BGMS stock, click here.
More about Bio Green Med Solution
YTD Price Performance: -98.24%
Average Trading Volume: 491,025
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.56M